Axicabtagene Ciloleucel Leads to ‘Continued Durable Responses’ in Indolent B-Cell Lymphoma in ZUMA-5 | Blood Cancers Today
Axicabtagene ciloleucel led to “continued durable responses” in patients with relapsed/refractory indolent non-Hodgkin lymphoma in the ZUMA-5 trial.